ArticleBritish journal of clinical pharmacology2025
A scoping review of disease-modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice.
Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A scoping review of disease-modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice.British journal of clinical pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsAdherence to disease-modifying antirheumatic drugs (DMARDs) has been associated with improved treatment outcomes, but how adherence is reported ranges between studies. We therefore aimed to determine how nonadherence to DMARDs used to treat rheumatoid arthritis (RA) has been measured and to report the nonadherence rate with each measure identified. Additionally, we aimed to explore what factors are associated with nonadherence.
methodsA scoping review was conducted in the following databases: Embase, Medline, Scopus and Cochrane, searching from 2000 up to 31 August 2022 using search terms related to 'adherence'; 'measures'; rheumatoid arthritis'; and 'medication'. Descriptive analyses were used to analyse and interpret the data according to the stated aims. We included 172 manuscripts that met the inclusion criteria and the median number of participants for each study was 249 (interquartile range 120-767). Measures of adherence included dispensing data, tablet counts, self-report and physician estimates, electronic monitors, questionnaires and blood assays.
resultsNonadherence was most commonly reported as a proportion and ranged from 1.5 to 100% for any DMARDs as a class, 0 to 95% for conventional synthetic DMARDs and 3 to 95% for biologic DMARDs. Increased disease activity, younger age and comorbidities were found in several studies to be associated with nonadherence, while there were inconsistent findings for sex, education, disease duration and other patient characteristics.
conclusionMuch variability exists in the reported prevalence of nonadherence in RA, in what measures are used to assess nonadherence, how nonadherence is reported and which patient characteristics are associated with nonadherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.